News
-
-
-
-
PRESS RELEASE
Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval
Mainz Biomed provides Q1 2025 corporate update on FDA premarket approval path, including study enrollment, partnership with Liquid Biosciences and labor team w ag, and product launches. CEO Guido Baechler comments on progress -
-
-
-
-
-
PRESS RELEASE
Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer
Mainz Biomed and Liquid Biosciences make groundbreaking discovery of mRNA biomarkers for blood-based detection of pancreatic cancer, achieving transformative sensitivity of 95% and specificity of 98%